CHKP Stock Check Point Software Technologies Ltd.
ACCUMULATE US · NasdaqGSHighly profitable security platform offers defensive quality and steady shareholder returns.
Future value: $146.47 (-8.24%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Institutional quality and recurring security demand support steady accumulation.
- ▸Above 50-day MA (+17.92%)
- ▸Above 200-day MA — long-term uptrend
- ▾Trading above its price target — limited upside
Is CHKP a buy right now?
Trend: CHKP is trading above the 50-day average (+17.92%), RSI 28 — oversold territory, with a 3-month return of +15.98%.
Valuation & quality: Check Point Software Technologies Ltd. trades on a trailing P/E of 16.3, forward P/E 14.2, PEG 1.41, price-to-book 6.00; fundamentals show net margin 37.9%, return on equity 37.6%, revenue growth 1.3% year on year.
Analyst consensus: 31 analysts have a mean 12-month price target of $147.12 (-7.8% vs the last close; range $105.00 – $201.00), consensus rating “buy”.
Our screen: ACCUMULATE (score 1) — Highly profitable security platform offers defensive quality and steady shareholder returns.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -6.10% | -21.30% | +20.10% | -2.70% | -3.30% | +9.30% | -7.60% | +24.40% |
Fundamentals
Analyst price target
Technical signals
About Check Point Software Technologies Ltd.
Check Point Software Technologies Ltd. develops, markets, and supports a range of products and services for IT security worldwide. It provides a multilevel security architecture that defends enterprises' cloud, network, mobile devices, endpoints information, and IOT solutions.
Sector: Technology · Industry: Software - Infrastructure · Israel · 6,825 employees · Website
Related Cybersecurity picks
Browse: all US stocks · Cybersecurity picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.